Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?

Health Economics, Policy and Law

Volumn 8, Issue 2, 2013, Pages 185-208

  Mueller Langer, Frank ^a  

^a MAX PLANCK INSTITUTE FOR INNOVATION AND COMPETITION   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ADVANCED PURCHASE COMMITMENT; ARTICLE; AWARDS AND PRIZES; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; NEGLECTED DISEASE; NEGLECTED INFECTIOUS DISEASE; PATENT BUYOUT; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PULL INCENTIVE PROGRAM; PUSH INCENTIVE PROGRAM; RESOURCE ALLOCATION; TAX; TAX CREDIT;

COMMUNICABLE DISEASES; FINANCING, ORGANIZED; HEALTH STATUS DISPARITIES; HUMANS; MOTIVATION; ORPHAN DRUG PRODUCTION; PATENTS AS TOPIC; RARE DISEASES; REWARD;

EID: 84874876362     PISSN: 17441331     EISSN: 1744134X     Source Type: Journal    
DOI: 10.1017/S1744133112000321     Document Type: Article

References (49)

1. Acemoglu, D. and J. Linn (2004), 'Market size in innovation: theory and evidence from the pharmaceutical industry', Quarterly Journal of Economics, 119(3): 1049-1090. (Pubitemid 39057314)
2. Berndt, E. R., R. Glennerster, M. Kremer, J. Lee, R. Levine, G.Weizsäcker and H. L.Williams (2007), 'Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness', Health Economics, 16(4): 491-511. (Pubitemid 46784284)
3. Bhutta, Z. A., I. Gupta, H. de'Silva, D. Manadhar, S. Awasthi, S. M. Hossain and S. A. Salam (2004), 'Maternal and child health: Is South Asia ready for change?', BMJ, 328: 816-819. (Pubitemid 38446381)
4. Buckup, S. (2008), 'Global public-private partnerships against neglected diseases: building governance structures for effective outcomes', Health Economics, Policy and Law, 3: 31-50. (Pubitemid 351279992)
5. DiMasi, J. A., R. W. Hansen and H. G. Grabowski (2003), 'The price of innovation: new estimates of drug development costs', Journal of Health Economics, 22: 151-185. (Pubitemid 36279392)
6. Food and Drug Administration (FDA) (2011), 'A Review to FDA's Approach to Medical Product Shortages', FDA Report, 31 October 2011, Silver Spring, MD, USA.
7. Gallini, N. T. and S. Scotchmer (2002), 'Intellectual Property: When is it the Best Incentive System?', in A. B. Jaffe, J. Lerner and S. Stern (eds), NBER (National Bureau of Economic Research) Innovation Policy and the Economy, vol. 2. Cambridge, MA, USA: MIT Press, 51-77.
8. Glennerster, R. and M. Kremer (2001), 'A better way to spur medical research and development', Regulation, 23(2): 34-39.
9. Grabowski, H. G. (2005), 'Increasing R&D Incentives for Neglected Diseases: Lessons From the Orphan Drug Act', in K. E. Maskus and J. H. Reichman (eds), International Public Goods and Transfer of Technology Under a Globalized Intellectual Property Regime, Cambridge: Cambridge University Press, 457-480.
10. Grabowski, H. G. and J. M. Vernon (2000), 'The determinants of pharmaceutical research and development expenditures', Journal of Evolutionary Economics, 10(1/2): 201-215.
11. Hall, B. H. and J. van Reenen (2000), 'How effective are fiscal incentives for R&D? A review of the evidence', Research Policy, 29: 449-469.
12. Harhoff, D., F. M. Scherer and K. Vopel (2003), 'Citations, family size, opposition and the value of patent rights', Research Policy, 32(8): 1343-1363.
13. Hollis, A. (2007), 'Drugs for Neglected Diseases: New Incentives for Innovation', in F. A. Sloan and C. R. Hsieh (eds), Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, Cambridge: Cambridge University Press, 75-90.
14. Hollis, A. and P. Pogge (2008), The Health Impact Fund: Making New Medicines Accessible for All, New Haven, CT: Incentives for Global Health.
15. Kettler, H. E. and R. Modi (2001), 'Building research and development capacity for the prevention and cure of neglected diseases: the case of India', Bulletin of the World Health Organization, 79(8): 742-747. (Pubitemid 32776843)
16. Kremer, M. (1998), 'Patent buyouts: a mechanism for encouraging innovation', Quarterly Journal of Economics, 113(4): 1137-1167. (Pubitemid 128360921)
17. Kremer, M. (2001), 'Creating Markets for New Vaccines: Part I: Rationale', in A. B. Jaffe, J. Lerner and S. Stern (eds), NBER Innovation Policy and the Economy, vol. 1. Cambridge, MA, USA: MIT Press, 35-72.
18. Kremer, M. (2002), 'Pharmaceuticals and the developing world', Journal of Economic Perspectives, 16(4): 67-90.
19. Kremer, M. and R. Glennerster (2000), 'A world bank vaccine commitment', Brookings Institution Policy Brief, 57: 1-8.
20. Kremer, M. and R. Glennerster (2004), Strong Medicine, Creating Incentives for Pharmaceutical Research and Neglected Diseases, New Jersey: Princeton University Press.
21. Kremer, M. and H. Williams (2010), 'Incentivizing Innovation: Adding to the Tool Kit', in J. Lerner and S. Stern (eds), NBER Innovation Policy and the Economy, vol. 10. Chicago, IL, USA: University of Chicago Press, 1-17.
22. Lanjouw, J. O. (2003), 'Intellectual Property and the Availability of Pharmaceuticals in Poor Countries', in A. B. Jaffe, J. Lerner and S. Stern (eds), NBER Innovation Policy and the Economy, vol. 3. Cambridge, MA, USA: MIT Press, 91-129.
23. Layne-Farrar, A. and K. M. Schmidt (2010), 'Licensing complementary patents: "patent trolls", market structure, and "excessive royalties"', Berkeley Technology Law Journal, 25: 1121-1144.
24. Lichtenberg, F. R. and J. Waldfogel (2003), Does Misery Love Company? Evidence From Pharmaceutical Markets Before and After the Orphan Drug Act, NBERWorking Paper, No. 9750, Washington, DC: National Bureau of Economic Research.
25. Liddell, K. (2010), 'The Health Impact Fund: A Critique', in T. Pogge, M. Rimmer and K. Rubenstein (eds), Incentives for Global Public Health: Patent Law and Access to Essential Medicines, Cambridge: Cambridge University Press, 155-180.
26. Link, M. P., K. Hagerty and H. M. Kantarjian (2012), 'Chemotherapy drug shortages in the United States: genesis and potential solutions', Journal of Clinical Oncology, 30(7): 692-694.
27. Love, J. and T. Hubbard (2007), 'The big idea: prizes to stimulate R&D for new medicines', Chicago-Kent Law Review, 82(3): 1519-1554.
28. Lybecker, K. M. and R. A. Freeman (2007), 'Funding pharmaceutical innovation through direct tax credits', Health Economics, Policy and Law, 2: 267-284.
29. Maurer, S. M. (2005), The Right Tool(s): Designing Cost-Effective Strategies for Neglected Disease Research, Report to WHO Commission on Intellectual Property Rights, Innovation and Public Health, Geneva: WHO.
30. Mrazek, M. F. and E. Mossialos (2003), 'Stimulating pharmaceutical research and development for neglected diseases', Health Policy, 64: 75-88. (Pubitemid 36315764)
31. Mueller-Langer, F. (2012), 'Parallel trade and its ambiguous effects on global welfare', Review of International Economics, 20(1): 177-185.
32. Pogge, T. (2010), 'The Health Impact Fund: Better Pharmaceutical Innovations at Much Lower Prices', in T. Pogge, M. Rimmer and K. Rubenstein (eds), Incentives for Global Public Health: Patent Law and Access to Essential Medicines, Cambridge: Cambridge University Press, 135-154.
33. Ricklin, D. and J. D. Lambris (2007), 'Complement-targeted therapeutics', Nature Biology, 25(11): 1265-1275. (Pubitemid 350089828)
34. Ridley, D. B., H. G. Grabowski and J. L. Moe (2006), 'Developing drugs for developing countries', Health Affairs, 25(2): 313-324. (Pubitemid 43529539)
35. Rogoyski, R. (2006), 'The orphan drug act and the myth of the exclusivity incentive', The Columbia Science and Technology Law Review, 7(Article 4): 1-22.
36. Shulman, S. R. and M. Manocchia (1997), 'The U. S. orphan drug programme: 1983-1995', PharmacoEconomics, 12(3): 312-326.
37. Singer, P. A. and A. S. Daar (2001), 'Harnessing genomics and biotechnology to improve global health equity', Science, 294: 87-89. (Pubitemid 32952953)
38. Sonderholm, J. (2009), 'Wild-card patent extensions as a means to incentivize research and development of antibiotics', Journal of Law, Medicine and Ethics, 37(2): 240-246.
39. Spellberg, B., L. G. Miller, M. N. Kuo, J. Bradley, W. M. Scheld and J. E. Edwards (2007), 'Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development', Infection, 35(3): 167-174. (Pubitemid 46932331)
40. Stiglitz, J. E. and A. Jayadev (2010), 'Medicine for tomorrow: some alternative proposals to promote socially beneficial research and development in pharmaceuticals', Journal of Generic Medicines, 7(3): 220-221.
41. Thorsteinsdó ttir, H., T. W. Sáenz, U. Quach, A. S. Daar and P. A. Singer (2004), 'Cuba-innovation through synergy', Nature Biotechnology, 22: DC19-DC24.
42. Travis, P., S. Bennett, A. Haines, T. Pang, Z. Bhutta, A. A. Hyder, N. R. Pielemeier, A. Mills and T. Evans (2004), 'Overcoming health-systems constraints to achieve the Millennium Development Goals', Lancet, 364: 900-906. (Pubitemid 39221069)
43. Trouiller, P., P. Olliaro, E. Torreele, J. Orbinski, R. Laing and N. Ford (2002), 'Drug development for neglected diseases: a deficient market and a public-health policy failure', Lancet, 359(9324): 2188-2194. (Pubitemid 34694030)
44. Trouiller, P., E. Torreele, P. Olliaro, N. White, S. Foster, D. Wirth and B. Pécoul (2001), 'Drugs for neglected diseases: a failure of the market and a public health failure?', Tropical Medicine and International Health, 6(11): 945-951. (Pubitemid 33010882)
45. Villa, S., A. Compagni and M. R. Reich (2009), 'Orphan drug legislation: lessons for neglected tropical diseases', International Journal of Health Planning and Management, 24(1): 27-42.
46. Webber, D. and M. Kremer (2001), 'Perspectives on stimulating industrial research and development for neglected infectious diseases', Bulletin of theWorld Health Organization, 79(8): 735-741. (Pubitemid 32776842)
47. WHO World Health Organization (1996), Investing in Health Research and Development, Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options, Geneva: World Health Organization.
48. WHO (2001), World Health Report 2001, Geneva: World Health Organization.
49. WHO (2008), The Global Burden of Disease: 2004 Update, Geneva: World Health Organization.